SAJAZIR

Serial Number 90461564
Registration 7081259
700

Registration Progress

Application Filed
Jan 12, 2021
Under Examination
Oct 18, 2022
Approved for Publication
Aug 23, 2022
Published for Opposition
Aug 23, 2022
Registered
Jun 13, 2023

Trademark Image

SAJAZIR

Basic Information

Serial Number
90461564
Registration Number
7081259
Filing Date
January 12, 2021
Registration Date
June 13, 2023
Published for Opposition
August 23, 2022
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 13, 2023
Registration
Registered
Classes
005

Rights Holder

Cycle Pharmaceuticals Ltd.

99
Address
The Broers Building
21 JJ Thomson Ave
Cambridge CB30FA
GB

Ownership History

Cycle Pharmaceuticals Ltd.

Original Applicant
99
Cambridge GB

Cycle Pharmaceuticals Ltd.

Owner at Publication
99
Cambridge GB

Cycle Pharmaceuticals Ltd.

Original Registrant
99
Cambridge GB

Legal Representation

Attorney
Mary Frances Love

USPTO Deadlines

Next Deadline
1427 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-06-13)
Due Date
June 13, 2029
Grace Period Ends
December 13, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

31 events
Date Code Type Description Documents
Jun 13, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 13, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
May 9, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
May 8, 2023 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
May 4, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 4, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Apr 18, 2023 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Apr 18, 2023 IUAF S USE AMENDMENT FILED Loading...
Oct 18, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 23, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 23, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 3, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 15, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 14, 2022 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Jul 14, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jul 14, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 1, 2022 CNFR R FINAL REFUSAL WRITTEN Loading...
Feb 1, 2022 GNFR O FINAL REFUSAL E-MAILED Loading...
Feb 1, 2022 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Jan 20, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jan 20, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 20, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 5, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Aug 5, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 5, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Jul 28, 2021 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 28, 2021 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 28, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 21, 2021 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 12, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 15, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical agents for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceutical preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceuticals for the treatment of hereditary angioedema all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Veterinary preparations for treatment of intestinal bacteria; veterinary preparations, namely, antioxidants; veterinary preparations, namely, pain relief medications; veterinary preparations for medical treatment of chronic illnesses; veterinary preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans and animals; supplements for the treatment of hereditary angioedema; supplements for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; food for babies; medical dressings; plasters for medical purposes; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; biological preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; chemical preparations for the medical treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; Drug delivery agents consisting of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents for use in pharmaceutical preparations, drugs and medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medical drugs for the treatment of rare diseases, in particular for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for medical purposes, enzyme preparations for the treatment of hereditary angioedema, medical enzyme preparations in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for veterinary purposes; medicinal preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Medical and veterinary preparations and articles, namely, pre-filled syringes containing a bradykinin B2 receptor antagonist for medical purposes; Pharmaceuticals and natural remedy preparations, for use in the treatment and management of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist; syringes sold filled with a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema
First Use Anywhere: Sep 23, 2022
First Use in Commerce: Sep 23, 2022

Additional Information

Translation
The wording SAJAZIR has no meaning in a foreign language.

Classification

International Classes
005